Inclusion criteria often require liver biopsy showing fibrosis (F2/3) or cirrhosis (F4) and nonalcoholic steatohepatitis (NASH). However, histological criteria pose a serious obstacle for recruitment. Aims: Characterize the relevance of liver biopsies in the selection of patients with NAFLD. Methods:...
The proportion of non-cirrhotic NASH with MALF was informed by analyses of the Forian US integrated medical claims database using NASH and cirrhosis-specific ICD-10-CM codes and FIB-4 scores. NASH diagnosis rates were obtained from published estimates and NHANES responses. Treatment-eligible ...
Patients diagnosed with NAFLD or NASH and cirrhosis between January 2016 and December 2019 were identified utilizing appropriate ICD-10-CM codes. The primary outcome was 3-year overall survival. Secondary outcomes were decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation. The ...
In line, transplantation of MSCs decreased fibrosis and activation of hepatic stellate cells in mouse and rat liver cirrhosis triggered by carbon tetrachloride (CCl4) [21,22]. MSC restored ammonia and purine metabolism in a mouse model of acute liver failure [23], improved acute liver injury ...